BioClinica

Industry / private company

Location: Princeton, NJ

ISNI: 0000000406021531

ROR: https://ror.org/03t95yr58

Show on Map:

Publications

(7)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (2021) Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, et al. Journal article Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass (2017) Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, et al. Journal article Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2) (2015) Roemer F, Hayes CW, Miller CG, Hoover K, Guermazi A Journal article OARSI Clinical Trials Recommendations: Hand imaging in clinical trials in osteoarthritis (2015) Hunter DJ, Arden N, Cicuttini FM, Crema MD, Dardzinski B, Duryea J, Guermazi A, et al. Journal article, Review article Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1) (2015) Roemer F, Hayes CW, Miller CG, Hoover K, Guermazi A Journal article Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3) (2015) Roemer F, Hayes CW, Miller CG, Hoover K, Guermazi A Journal article The current status of imaging in anti-NGF clinical trials (2015) Miller CG, Guermazi A, Roemer F Journal article